Alqaem and Biosign to exhibit UFIT TEN-20 non-invasive glucometer at 36th Arab Health Exhibition

ALQAEM International (FZE) ("Alqaem" or the "Company"), exclusive Biosign master distributor for the Middle East and North Africa Region (M.E.N.A.) today announced that they will be joining with Biosign Technologies Inc (TSX-V:BIO), the Canadian manufacturer of the revolutionary UFIT(R)TEN-20 non-invasive glucometer, to exhibit at the 36th Annual Arab Health Exhibition & Congress held in Dubai, UAE from January 24th to 27th, 2011 at Stand S1G61.

The Arab Health Exhibition & Congress is, by far, the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar.

John Rizvi, Managing Director of ALQAEM, stated: "Each year, over 66,000 professionals from 145 countries attend the Arab Health Exhibition. We are excited to work directly with Biosign at such a prestigious event, and we look forward to introducing the remarkable new UFIT(R)TEN-20 a non-invasive glucometer to customers, resellers and medical professionals from the M.E.N.A. region and all over the World. We anticipate an enthusiastic response to the Biosign UFIT(R) non-invasive solution!"

UFIT(R) TEN-20 is an online medical device for self-monitoring of blood pressure and blood glucose. The device takes the pulse at the wrist through an inflatable cuff and immediately produces blood pressure and blood glucose measurement results. All measurements are indirect, noninvasive, and passive. The results are stored on Biosign servers along with the test sample. Readings can be viewed by care providers on a secure web portal and/or integrated into a patient's Electronic Health Record (EHR). The UFIT(R) TEN-20 is approved under ISO 13485 for the non-invasive measurement of blood pressure and blood glucose, and carries the CE Mark.

SOURCE Alqaem International